Naji C. Salloum, MD

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...

To optimize treatment choices for patients with treatment-resistant depression (TRD), TRD should be defined accurately and unambiguously. This review examines extant descriptions and staging models of TRD and posits...